All News

mtx.png (keep)

Safety and Tolerability of Subcutaneous Methotrexate

d Jack Cush, MD

A large, single-rheumatology center analysis of oral and subcutaneous (SC) methotrexate (MTX) use in daily clinical practice suggests that SC MTX has fewer drug discontinuations and is better tolerated compared to other DMARD therapies.

Read Article
RheumNow Podcast square

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

d Jack Cush, MD

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
FDA issued Drug Safety Communication to statin manufacturers requesting they remove strong warnings against statin use during pregnancy. While statins appear in breast milk, they should not be contraindicated, if needed, during Pregnancy https://t.co/AeFwpsLMXT

Links:

Dr. John Cush RheumNow ( View Tweet)

Pfizer has another JAK inhibitor - ritlecitinib - shown to be effective (vs PBO) in alopecia areata in the Phase 2b/3 ALLEGRO trial. Ritlecitinib is also being studied in vitiligo, rheumatoid arthritis, Crohn’s & ulcerative colitis. https://t.co/ccx0eRXuTS https://t.co/fApTP7WaYU

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-6 Inhibitor Safety Issues-Download now! https://t.co/rjId76sJ64 https://t.co/QwBJNmrzBf

Links:

Dr. John Cush RheumNow ( View Tweet)
In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@wk16, UPA 71% vs DUP 61% https://t.co/5cOoosKyao

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast available for download! https://t.co/5K8ejJ4jj2 https://t.co/Va66dLGrXO

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/MiaIqvMPaB

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: D-penicillamine Adverse events reported to FDA (1970-2020): dystonia (OR 20.52), drug hypersensitivity (OR 5.42), pancytopenia (OR 10.2), joint swelling (OR 9.07), Renal (OR 6.68), dysphagia (OR 5.05), CHF (OR 4.04), edema (OR: 3.77) https://t.co/8lmYiJo2Tz

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: CRESS – A New Composite Measure for Primary Sjögren's Syndrome https://t.co/7tvjBvP3g4

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: JRheum review: 40–50% of psoriasis pts have psoriatic nail disease NP). NP is an important predictor of enthesitis, which is associated with the early stages of PsA https://t.co/sEuih3CSgX

Links:

Dr. John Cush RheumNow ( View Tweet)

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy & safety; and an interesting case plus a question from one of our readers submitted. This and more in this week's podcast. Let's dive in. https://t.co/5K8ejJ4jj2 https://t.co/pqCsvYuI96

Links:

Dr. John Cush RheumNow ( View Tweet)
Veterans study gout prevalence rose from 4.2% to 5.8%, 2005 to 2014. 2014, 4.0% of all inpatient/outpatient encounters & 1.3% of hospitalizations were gout related. ULT use remained stable with 46% of gout patients receiving ULT https://t.co/Lmf2mmMddW

Links:

Dr. John Cush RheumNow ( View Tweet)

Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/f4WdkRZWpM

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatic Flares Uncommon After COVID Vax https://t.co/fuyC50K5UF Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found. https://t.co/jp0ZoRqnla

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 708 newly Dx rotator cuff disorder shows that 6 sessions of Progressive exercise was not superior to a 1 physiotherapist session in improving shoulder pain and function. Subacromial corticosteroid injection provided no long-term benefits https://t.co/Flqv286MVV

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 1821 pregnant women with autoimmune disorder. 74% used acetaminophen during pregnancy (HA, pain, injury). The highest (5th quintile use thru wk 20) acetaminophen had a modest risk (HR 1.62) of preeclampsia vs none https://t.co/DXxaSkTZs7

Links:

Dr. John Cush RheumNow ( View Tweet)

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases https://t.co/xftj12BgzX #medRxiv

Links:

medRxiv medrxivpreprint ( View Tweet)

The Israeli data for increased mRNA-vaccination breakthrough infections and "waning immunity" is finally available https://t.co/9j73Q7L7Nn h/t @Aiims1742 Overall 2X risk, no statistical significant difference between age groups, but trend of increase w/ age https://t.co/D4IpFm6Ydl

Links:

Eric Topol EricTopol ( View Tweet)
D-penicillamine Adverse events reported to FDA (1970-2020): dystonia (OR 20.52), drug hypersensitivity (OR 5.42), pancytopenia (OR 10.2), joint swelling (OR 9.07), Renal (OR 6.68), dysphagia (OR 5.05), CHF (OR 4.04), edema (OR: 3.77) https://t.co/8lmYiJo2Tz

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×